American College of Clinical Pharmacy
      Search      Cart
         

Sat-3 - Effects of Alpha-Lipoic Acid on Serum Uric Acid in Patient with Type 2 Diabetes: A Retrospective Study

Scientific Poster Session I - Original Research

Original Research
  Saturday, November 11, 2023
  11:30 AM–01:00 PM

Abstract

Introduction:

Types 2 diabetes (T2DM) is highly associated with asymptomatic hyperuricemia and there is no medicine recommendation for T2DM patients with serum uric acid at 420 µmol/L = x < 480 µmol/L.

Research Question or Hypothesis: Whether alpha-lipoic acid (ALA) which is used for diabetic peripheral neuropathy has effect on serum uric acid in patients with T2DM.

Study Design: A retrospective one-arm study

Methods:

Patients who received ALA treatment at Zhongda Hospital between January 2017 and December 2022 were stratified and paired according to gender, age, diabetes duration, and renal function. Wilcoxon rank-sum test was used to analyze the differences in serum uric acid, creatinine, estimated glomerular filtration rate (eGFR), and other indicators before and after ALA treatment. Multiple linear regression analysis was performed to determine the independent association between potential predictor variables and serum uric acid level as the dependent variable.

Results: A total of 163 eligible cases were included based on the inclusion and exclusion criteria. The results showed that serum uric acid levels were significantly decreased (P<0.05) after treatment in patients with all stratified in diabetes durations and renal function grades. In the stratified patients aged =50 years or with a pre-treatment serum uric acid level of 300 µmol/L = x < 540 µmol/L, serum uric acid was significantly reduced after treatment (P<0.05). Multiple linear regression analysis showed that pre-treatment serum uric acid level (P<0.01) was the main influencing factor of the uric acid reduction after treatment.

Conclusion:

ALA can significantly reduce serum uric acid levels in patients aged =50 years or with a pre-treatment serum uric acid level of 300 µmol/L = x < 540 µmol/L, and the higher the pre-treatment serum uric acid level, the more significant the reduction after treatment. These results indicate ALA is a potential medicine to treat asymptomatic hyperuricemia in T2DM.

Presenting Author

Xueli Zhang PhD
School of Medicine, Southeast University

Authors